|
|
 |
|
Viewing report
|
|
|
|
Industry Analysis: Where Is the Innovation in Neurology Markets?
Decision Resources, Inc, Nov 2006, Pages: 30
The four major neurological diseases currently have no cures. Many pharmaceuticals are available and are in development, but these drugs typically address just the symptoms. Vast unmet need exists for medicines that treat the early stages of neurological diseases. And, in turn, a huge opportunity exists for companies that focus on innovation.
Get the Answers You Need to Shape Your Strategy
There are more than a dozen major neurology franchises, and many companies have had blockbuster success in this market. Yet the unmet need and resulting opportunity in this market are staggering. What business strategies can companies utilize to tap this wide-open market? Most medicines on the market offer only symptomatic relief, and few new innovative drugs are in development. What approaches can companies use to create drugs with disease-modifying effects and to treat early-stage disease?
Companies are using many life-cycle management strategies to extend the market for existing drugs. While these drugs are useful, they do little to build value for the future. Why are so few products available for neurological diseases? What explains the lack of innovation in this market? What strategies are companies using to develop future neurology drug markets and franchises?
Scope
Overview of drugs and market for the four major neurology diseases: Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis.
Key neurology deals: overview of ten neurology deals valued at more than $100 million that have closed within the last two years.
Business strategies that companies are using to develop future neurology drug markets and franchises: in-licensing, mergers and acquisitions, fully integrated companies, challenging drug patents, extending reach from generics to brands.
Decision points critical to innovation in the neurology market: resource allocation and
prioritization, how to treat early-stage disease, creating personalized medicine, stem cell research.
Spectrum Expert Commentary: the view from a world-known pharmaceutical industry
consultant.
Outlook: challenges that the neurology market will face without innovation.
Lulu Pickering, Ph.D.
Decision Resources, Inc
|
|
|
|
